Gilteritinib

Chemical formula: C₂₉H₄₄N₈O₃  Molecular mass: 552.724 g/mol  PubChem compound: 49803313

Therapeutic indications

Gilteritinib is indicated for:

Ρelapsed or refractory acute myeloid leukaemia with a FLT3 mutation

Population group: only adults (18 years old or older)

Gilteritinib is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Gilteritinib is contraindicated in the following cases:

Lactation

Lactation

Prolonged QT interval QTcF >500 msec

Prolonged QT interval

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2023: XOSPATA Film-coated tablet
Structured Product Labeling (SPL/PLR) 2019: XOSPATA Tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈